Compositions and methods for silencing SCN9A expression
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsWilliam Cantley, James D. McIninch, Adam Castoreno, Charalambos Kaittanis, Mark K. Schlegel
Life of this patent
Estimating the term…
Abstract
The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting SCN9A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of SCN9A.
Claims18
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of sodium channel, voltage gated, type IX alpha subunit (SCN9A), wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0 or 1 mismatch, from the antisense sequence set forth as SEQ ID NO:
- 5093 and wherein the sense strand comprises a nucleotide sequence comprising at least 17 contiguous nucleotides, with 0 or 1 mismatch, from a sense sequence set forth as SEQ ID NO:
- 4827.
Dependencies are inferred from the claim text.